PIK3CA and glioblastoma: We investigated whether a combination of the dual pan-Class I PI3K/mTOR inhibitor PI-103 [13–15] with TMZ in paediatric glioblastoma cell lines would show changes in their metabolic profiles that could be detected with NMR.